Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC) (Q114738429)
Jump to navigation
Jump to search
scientific article published on 06 March 2020
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC) |
scientific article published on 06 March 2020 |
Statements
Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC) (English)
W. R. Gerritsen
A. J. van den Eertwegh
T. D. de Gruijl
G. Giaccone
R. J. Scheper
N. Sacks
T. Harding
I. Lowy
E. Stankevich
K. Hege
6 March 2020
18_suppl
5120-5120